Hepatitis C
AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
- Details
- Category: HCV Treatment
- Published on Tuesday, 31 October 2017 00:00
Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 31 October 2017 00:00
People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
Merck Discontinues Development of Experimental Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 12 October 2017 00:00
Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.
AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 31 October 2017 00:00
Hepatitis C incidence is increasing among gay and bisexual men living with HIV in San Diego, according to the largest analysis of its kind done in the United States. Study results were presented last week at the 2017 AASLD Liver Meeting in Washington, DC.
Does Drug Injection Equipment Other than Syringes Transmit Hepatitis C?
- Details
- Category: Injection Drug Use
- Published on Thursday, 21 September 2017 00:00
Sharing drug preparation paraphernalia may not significantly contribute to hepatitis C virus (HCV) transmission among people who inject drugs, according to a study recently published in the Journal of Infectious Diseases.
EACS 2017: Test-and-Treat Reduces HCV Among Gay Men in Swiss HIV Cohort
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 31 October 2017 00:00
A systematic policy of test-and-treat cured 99% of men who have sex with men with hepatitis C in the Swiss HIV Cohort during an 8-month period and reduced the prevalence of hepatitis C by almost two-thirds, Dominique Braun of the University Hospital, Zurich, reported at the recent 16th European AIDS Conference (EACS 2017) in Milan.
INHSU 2017: People Who Use Drugs Should Be Prioritized for Hepatitis C Treatment
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 21 September 2017 00:00
People who use drugs should be given high priority for antiviral treatment as a way to eliminate hepatitis C as a public health concern, according to a statement issued at the 6th International Symposium on Hepatitis Care in Substance Users, held earlier this month in Jersey City.
EACS 2017: High Rate of Hepatitis C Reinfection in German Men Who Have Sex With Men
- Details
- Category: HCV Sexual Transmission
- Published on Sunday, 29 October 2017 00:00
Around 1 in 7 gay and bisexual men cured of hepatitis C at major treatment centers in Germany have become reinfected since 2014, according to findings from the German Hepatitis C Cohort presented at the 16th European AIDS Conference (EACS 2017) in Milan in October. At least half of these men became reinfected within a year of completing treatment and all reinfections occurred within 18 months.
Janssen Discontinues Hepatitis C Drug Development Program
- Details
- Category: HCV Treatment
- Published on Thursday, 21 September 2017 00:00
Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.
More Articles...
- Experts Question Cochrane Review of Hepatitis C DAA Treatment
- New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment
- IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection
- FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C
- IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa
Web Design and Development by